Brendan D. Curti

15.8k total citations · 2 hit papers
185 papers, 6.3k citations indexed

About

Brendan D. Curti is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Brendan D. Curti has authored 185 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Oncology, 71 papers in Immunology and 41 papers in Molecular Biology. Recurrent topics in Brendan D. Curti's work include Cancer Immunotherapy and Biomarkers (88 papers), CAR-T cell therapy research (71 papers) and Immunotherapy and Immune Responses (57 papers). Brendan D. Curti is often cited by papers focused on Cancer Immunotherapy and Biomarkers (88 papers), CAR-T cell therapy research (71 papers) and Immunotherapy and Immune Responses (57 papers). Brendan D. Curti collaborates with scholars based in United States, France and United Kingdom. Brendan D. Curti's co-authors include Walter J. Urba, Mark B. Faries, Bruce G. Redman, Ronald M. Bukowski, Kim Margolin, Robert J. Motzer, Gary R. Hudes, John W. Smith, Daniel J. George and George Wilding and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Brendan D. Curti

179 papers receiving 6.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

2006 969 citations Brendan D. Curti, Kim Margolin et al. profile →
Recent Advances in the Treatment of Melanoma

2021 235 citations Brendan D. Curti et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brendan D. Curti United States	40	3.4k	2.4k	2.1k	1.9k	935	185	6.3k
Gabriel Sica United States	38	4.0k 1.2×	3.0k 1.2×	2.0k 0.9×	1.3k 0.7×	768 0.8×	97	6.9k
Raanan Berger Israel	34	4.2k 1.2×	1.6k 0.7×	2.2k 1.0×	1.9k 1.0×	1.2k 1.3×	160	7.2k
Yosuke Togashi Japan	39	4.2k 1.2×	2.0k 0.8×	1.6k 0.7×	2.3k 1.3×	866 0.9×	156	6.4k
Noriomi Matsumura Japan	41	3.7k 1.1×	2.4k 1.0×	2.5k 1.1×	891 0.5×	1.4k 1.5×	212	7.9k
Evan J. Lipson United States	41	5.9k 1.7×	2.2k 0.9×	1.4k 0.7×	1.6k 0.9×	642 0.7×	126	7.7k
Justus Duyster Germany	52	2.4k 0.7×	1.5k 0.6×	3.9k 1.8×	1.1k 0.6×	1.2k 1.2×	261	9.0k
Han Chong Toh Singapore	41	2.7k 0.8×	2.1k 0.9×	1.8k 0.9×	789 0.4×	1.2k 1.2×	134	6.1k
Hirotoshi Dosaka‐Akita Japan	50	3.5k 1.0×	2.1k 0.9×	2.6k 1.2×	3.0k 1.6×	856 0.9×	164	8.4k
Ravi A. Madan United States	43	4.3k 1.3×	3.2k 1.4×	1.5k 0.7×	2.2k 1.2×	650 0.7×	286	6.7k
Antonio Jimeno United States	39	3.5k 1.0×	1.0k 0.4×	3.5k 1.6×	1.4k 0.8×	1.3k 1.4×	169	7.2k

Countries citing papers authored by Brendan D. Curti

Since Specialization

Citations

This map shows the geographic impact of Brendan D. Curti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan D. Curti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan D. Curti more than expected).

Fields of papers citing papers by Brendan D. Curti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendan D. Curti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan D. Curti. The network helps show where Brendan D. Curti may publish in the future.

Co-authorship network of co-authors of Brendan D. Curti

This figure shows the co-authorship network connecting the top 25 collaborators of Brendan D. Curti. A scholar is included among the top collaborators of Brendan D. Curti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendan D. Curti. Brendan D. Curti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moser, Justin C., Mateusz Opyrchal, Brendan D. Curti, et al.. (2024). A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2623–2623. 2 indexed citations

Algazi, Alain P., James Moon, Christopher D. Lao, et al.. (2024). A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers. Cancer. 130(10). 1784–1796. 6 indexed citations

Le, Catherine T., Cordelia Dunai, Lam T. Khuat, et al.. (2023). Regulation of human and mouse bystander T cell activation responses by PD-1. JCI Insight. 8(18). 6 indexed citations

Simon, George R., Chiharu Sako, Ryan Beasley, et al.. (2023). AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.. Journal of Clinical Oncology. 41(16_suppl). 1517–1517. 1 indexed citations

Moser, Justin C., Mateusz Opyrchal, Brendan D. Curti, et al.. (2023). Abstract CT133: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors. Cancer Research. 83(8_Supplement). CT133–CT133. 1 indexed citations

Kottschade, Lisa A., Gregory R. Pond, Anthony J. Olszanski, et al.. (2023). SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 29(12). 2220–2225. 7 indexed citations

Piperno‐Neumann, Sophie, Piotr Rutkowski, J.F. Baurain, et al.. (2023). LBA50 Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial. Annals of Oncology. 34. S1289–S1290.

Goldman, Jonathan W., Sarina A. Piha‐Paul, Brendan D. Curti, et al.. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(17). 3709–3719. 19 indexed citations

Clark, Joseph I., Brendan D. Curti, Elizabeth J. Davis, et al.. (2021). Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. Journal of Investigative Medicine. 69(4). 888–892. 15 indexed citations

10.

Duhen, Rebekka, Carmen Ballesteros‐Merino, Alexandra K. Frye, et al.. (2021). Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nature Communications. 12(1). 1047–1047. 114 indexed citations

11.

Silk, Ann W., Howard L. Kaufman, Brendan D. Curti, et al.. (2020). High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology. 9. 1483–1483. 9 indexed citations

12.

Middleton, Mark R., Joseph J. Sacco, Jaime R. Merchan, et al.. (2019). Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors. Journal for ImmunoTherapy of Cancer. 7. 1 indexed citations

13.

Bentebibel, Salah-Eddine, Michael E. Hurwitz, Chantale Bernatchez, et al.. (2019). A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discovery. 9(6). 711–721. 169 indexed citations

14.

Naing, Aung, Sanjay Goel, Brendan D. Curti, et al.. (2016). A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors. Annals of Oncology. 27. vi367–vi367. 1 indexed citations

15.

Koguchi, Yoshinobu, Helena Hoen, Shelly Bambina, et al.. (2015). Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab. Cancer Research. 75(23). 5084–5092. 39 indexed citations

16.

Sckisel, Gail D., Myriam N. Bouchlaka, Arta M. Monjazeb, et al.. (2015). Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity. Immunity. 43(2). 240–250. 88 indexed citations

17.

Bhatia, Shailender, Brendan D. Curti, Michael A. Gordon, et al.. (2007). Recombinant IL-21 in combination with sorafenib: Preliminary results from a phase I/II study in patients with metastatic renal cell cancer. Molecular Cancer Therapeutics. 6. 2 indexed citations

18.

Smith, John W., W. Gregory Alvord, John E. Janik, et al.. (1993). The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin. New England Journal of Medicine. 328(11). 756–761. 98 indexed citations

19.

Curti, Brendan D.. (1993). Physical barriers to drug delivery in tumors. Critical Reviews in Oncology/Hematology. 14(1). 29–39. 23 indexed citations

20.

Ochoa, Juan B., Brendan D. Curti, Andrew B. Peitzman, et al.. (1992). Increased Circulating Nitrogen Oxides After Human Tumor Immunotherapy: Correlation With Toxic Hemodynamic Changes. JNCI Journal of the National Cancer Institute. 84(11). 864–867. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact